American Society of Hematology

How I Treat CLL: Have the New Targeted Treatments Changed the "Watch and Wait" Approach?

John C. Byrd, MD, The Ohio State University

Friday, September 8, 2017 3:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL

About the Speaker

John C_ Byrd

John C. Byrd, MD is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, where he also is the head of the Division of Hematology. Dr. Byrd’s research accomplishments relate best to work done between the laboratory and clinic with several therapeutic agents that are active against CLL. As a consequence of his detailed laboratory and clinical work, therapeutic agents such as rituximab, alemtuzumab, idelalisib, ibrutinib, and recently acalabrutinib have been identified as effective agents. He has transitioned over the past two years toward working also on developing new therapeutics for older patients with AML. He is one of the principals and Chief Medical Officer on a large multicenter trial called “Beat AML” sponsored by the Leukemia and Lymphoma Society which focuses on incorporating personalized targeted therapy for elderly patients. His primary goal of developing targeted agents is derived from his desire to offer patients non-toxic therapies with fewer side effects which ultimately impact their survival.

back to top